Results 21 to 30 of about 5,351 (123)

Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus [PDF]

Microbiology Spectrum
Despite the long therapy duration, the treatment outcomes for Mycobacterium abscessus lung disease (MAB-LD) are very poor. β-Lactams are among the recommended drugs for the treatment of MAB-LD; however, they are prone to hydrolysis by MAB β-lactamase ...
Avneesh Shrivastava, Gunavanthi D. Boorgula, Sanjay Singh, Danaleigh Stiles, Pamela J. McShane, Megan Devine, Tawanda Gumbo, Shashikant Srivastava   +7 more
doaj   +2 more sources

In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates. [PDF]

J Antimicrob Chemother
Objectives: To evaluate the in vitro activity of cefepime in association with a β-lactamase inhibitor (enmetazobactam) or β-lactam enhancer (BLE), zidebactam, against carbapenem-resistant Acinetobacter baumannii (CRAB) strains susceptible or resistant to
Tascini C, Bianco G, Bonomo RA, Gaibani P.   +3 more
europepmc   +2 more sources

Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam

Frontiers in Microbiology, 2021
Durlobactam is a new member of the diazabicyclooctane class of β-lactamase inhibitors with broad spectrum activity against Ambler class A, C, and D serine β-lactamases.
Adam B. Shapiro, Samir H. Moussa, Sarah M. McLeod, Thomas Durand-Réville, Alita A. Miller   +4 more
doaj   +1 more source

Sulbactam/Durlobactam: First Approval

, 2023
Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the ...
Susan Keam (4873372)
core   +1 more source

Sulbactam-durlobactam in combination with aztreonam and carbapenems against carbapenem-resistant Acinetobacter baumannii: an assessment using the MIC-based broth disk elution [PDF]

Journal of Clinical Microbiology
C. Koenig, D. P. Nicolau, T.E. Asempa
doaj   +2 more sources

Carbapenem‐Resistant Acinetobacter baumannii Bloodstream Infection in a Ghanaian Patient with Unilateral Diaphragmatic Eventration and HIV Type 1 Infection

Case Reports in Infectious Diseases, Volume 2023, Issue 1, 2023., 2023
Carbapenem‐resistant Acinetobacter baumannii infection is a critically prioritized pathogen by the World Health Organization and a cause for growing concern due to increased mortality among hospitalised patients. Phrenic nerve palsy is a rare complication of herpes zoster infection of the C3, C4, and C5 nerve roots.
Yvonne Ayerki Nartey, Augustine Boakye Donkor, Ampem Darko Jnr Siaw, Oluwayemisi Esther Ekor, Bashiru Babatunde Jimah, Dawei Cui   +5 more
wiley   +1 more source

The rising dominance of microbiology: what to expect in the next 15 years?

Microbial Biotechnology, Volume 15, Issue 1, Page 110-128, January 2022., 2022
Microbial research could lead to the development of in‐situ and ex‐situ rapid microbial detection systems based on microbial dark matter in the next 15 years. As a result of this anticipated shift, microbial cultivation will rapidly rise, altering the diversity of microorganisms and underlying lineages.
Roshan Kumar, Utkarsh Sood, Jasvinder Kaur, Shailly Anand, Vipin Gupta, Kishor Sureshbhai Patil, Rup Lal   +6 more
wiley   +1 more source

A randomized, double‐blind, placebo‐ and positive‐controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects

Clinical and Translational Science, 2021
Durlobactam (formerly ETX2514) is a diazabicyclooctane β‐lactamase inhibitor that inhibits class A, C, and D β‐lactamases. Sulbactam combined with durlobactam has in vitro and in vivo activity against Acinetobacter baumannii including carbapenem‐ and ...
John O’Donnell, Kathleen Maloney, Melissa Steidler, Royce Morrison, Robin Isaacs   +4 more
doaj   +1 more source

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii

, 2023
Infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) remain a clinical challenge due to limited treatment options. Recently, cefiderocol, a novel siderophore cephalosporin, and sulbactam-durlobactam, a bactericidal β-lactam–β ...
Pournaras, Spyros, Zarrilli, Raffaele, Karruli, Arta, Migliaccio, Antonella, Durante-Mangoni, Emanuele   +4 more
core   +1 more source

From clinical trials to daily practice: how to adequately administer sulbactam-durlobactam? alone or combined with imipenem? [PDF]

Curr Opin Infect Dis
Purpose of review: Sulbactam-durlobactam (SUL-DUR) is a novel β-lactam/β-lactamase inhibitor combination recently approved for carbapenem-resistant Acinetobacter baumannii (CRAB) infections.
Bonazzetti C, Giannella M, Pascale R.
europepmc   +2 more sources